Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD044
MIFTS: 51

Bladder Disease

Categories: Blood diseases, Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bladder Disease

About this section

MalaCards integrated aliases for Bladder Disease:

Name: Bladder Disease 38 12 15
Urinary Bladder Diseases 44 73
Bladder Diseases 55 43
Urinary Bladder Disease 12

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:365
ICD9CM 35 596.9
MeSH 44 D001745
NCIt 50 C2900
SNOMED-CT 68 42643001
UMLS 73 C0005686
Sources

Summaries for Bladder Disease

About this section
MedlinePlus : 43 The bladder is a hollow organ in your lower abdomen that stores urine. Many conditions can affect your bladder. Some common ones are Cystitis - inflammation of the bladder, often from an infection Urinary incontinence - loss of bladder control Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination Bladder cancer Doctors diagnose bladder diseases using different tests. These include urine tests, x-rays, and an examination of the bladder wall with a scope called a cystoscope. Treatment depends on the cause of the problem. It may include medicines and, in severe cases, surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Bladder Disease, also known as urinary bladder diseases, is related to cystitis and interstitial cystitis, and has symptoms including bladder fullness sensation An important gene associated with Bladder Disease is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Gastric cancer and Pathways in cancer. The drugs Hyaluronic acid and Mirabegron have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and heart, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A urinary system disease that is located in the bladder.

Wikipedia : 76 Urinary bladder disease includes urinary bladder inflammation such as cystitis, bladder rupture and... more...

Sources

Related Diseases for Bladder Disease

About this section

Diseases related to Bladder Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Related Disease Score Top Affiliating Genes
1 cystitis 32.1 HBEGF TRPV1 UPK3A
2 interstitial cystitis 29.7 CDH1 HBEGF TRPV1 UPK3A
3 bladder urothelial carcinoma 29.6 CDH1 FGFR3 TP53 UPK3A
4 transitional cell carcinoma 29.5 CDH1 FGFR3 TP53 UPK2 UPK3A
5 gallbladder disease 11.0
6 diphyllobothriasis 10.8
7 colorectal cancer, childhood 10.3 GSTM1 NAT2
8 actinic cheilitis 10.3 FGFR3 TP53
9 cerebral convexity meningioma 10.3 CDH1 TP53
10 hearing loss, noise-induced 10.3 GSTM1 GSTT1
11 bladder squamous cell carcinoma 10.3 TP53 UPK2
12 toxic oil syndrome 10.3 GSTM1 IDO1 NAT2
13 sister chromatid exchange, frequency of 10.3 GSTM1 GSTT1
14 invasive bladder transitional cell carcinoma 10.3 TP53 UPK3A
15 anaplastic thyroid cancer 10.3 CDH1 TERT TP53
16 stomach disease 10.3 CDH1 TP53 TRPV1
17 male reproductive system disease 10.2 CDH1 TP53 TRPV1
18 oral leukoplakia 10.2 GSTM1 GSTT1 TP53
19 toxic encephalopathy 10.2 GSTM1 GSTT1 TRPV1
20 reproductive system disease 10.2 CDH1 TP53 TRPV1
21 bladder carcinoma in situ 10.2 ELAVL3 TP53 UPK2
22 female reproductive system disease 10.2 CDH1 TP53 TRPV1
23 bladder papillary transitional cell neoplasm 10.2 FGFR3 PTCRA TERT TP53
24 urinary tract papillary transitional cell benign neoplasm 10.2 FGFR3 PTCRA TERT TP53
25 cardia cancer 10.2 GSTM1 GSTT1 TP53
26 pharynx cancer 10.2 CDH1 GSTM1 TP53
27 drug-induced hepatitis 10.2 GSTM1 GSTT1 NAT2
28 vulval paget's disease 10.2 PTCRA UPK3A
29 isolated cleft lip 10.2 GSTM1 GSTT1
30 intestinal disease 10.2 CDH1 TP53 TRPV1
31 diffuse gastric cancer 10.2 CDH1 GSTM1 GSTT1
32 oral submucous fibrosis 10.2 CDH1 GSTM1 GSTT1
33 renal hypodysplasia/aplasia 3 10.2 FGFR3 UPK3A
34 respiratory system disease 10.2 CDH1 TP53 TRPV1
35 gastrointestinal system disease 10.2 CDH1 HBEGF TP53 TRPV1
36 non-invasive bladder papillary urothelial neoplasm 10.2 FGFR3 PTCRA TP53 UPK3A
37 acute lymphocytic leukemia 10.2 GSTM1 GSTT1 TP53
38 respiratory system cancer 10.2 CDH1 GSTM1 TERT TP53
39 gastric diffuse adenocarcinoma 10.2 CDH1 UPK2
40 ureteral disease 10.2 CDH1 SLC3A1 SLC7A9 UPK3A
41 laryngeal squamous cell carcinoma 10.2 CDH1 GSTT1 TERT TP53
42 vulvar disease 10.2 TP53 UPK3A
43 adamantinoma of long bones 10.2 CDH1 GSTM1 TERT TP53
44 cholangiocarcinoma 10.2 CDH1 NAT2 TERT TP53
45 mutagen sensitivity 10.2 GSTM1 GSTT1 NAT2 TP53
46 suppression of tumorigenicity 12 10.2 CDH1 TP53 UPK3A
47 laryngeal disease 10.2 CDH1 GSTM1 GSTT1 TP53
48 oral cancer 10.2 CDH1 GSTM1 GSTT1 TP53
49 lung squamous cell carcinoma 10.2 CDH1 FGFR3 GSTM1 TP53
50 aplastic anemia 10.2 GSTM1 GSTT1 TERT TP53

Comorbidity relations with Bladder Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Bladder Disease:



Diseases related to Bladder Disease
Sources

Symptoms & Phenotypes for Bladder Disease

About this section

UMLS symptoms related to Bladder Disease:


bladder fullness sensation

GenomeRNAi Phenotypes related to Bladder Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.13 CDH1 FGFR3
2 Decreased viability GR00221-A-2 10.13 FGFR3
3 Decreased viability GR00221-A-3 10.13 FGFR3
4 Decreased viability GR00240-S-1 10.13 TP53
5 Decreased viability GR00301-A 10.13 CDH1
6 Decreased viability GR00381-A-1 10.13 CHRM3 GSTM1 PTCRA
7 Decreased viability GR00381-A-3 10.13 CHRM3
8 Decreased viability GR00402-S-2 10.13 BLNK CDH1 CHRM3 ELAVL3 FGFR3 GSTM1
9 no effect GR00402-S-1 9.62 BLNK CDH1 CHRM3 ELAVL3 FGFR3 GSTM1

MGI Mouse Phenotypes related to Bladder Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 CDH1 CHRM3 ELAVL3 FGFR3 HBEGF IDO1
2 immune system MP:0005387 9.85 BLNK CDH1 FGFR3 IDO1 PTCRA SLC3A1
3 neoplasm MP:0002006 9.43 BLNK CDH1 FGFR3 TERT TP53 TRPV1
4 renal/urinary system MP:0005367 9.28 CHRM3 FGFR3 IDO1 SLC3A1 SLC7A9 TP53
Sources

Drugs & Therapeutics for Bladder Disease

About this section

Drugs for Bladder Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 628)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Not Applicable 9004-61-9 53477741
2 Mirabegron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 223673-61-8
3
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-84-3 187
4
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5633-20-5 4634
5
Doxazosin Approved Phase 4 74191-85-8 3157
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
7
Midazolam Approved, Illicit Phase 4,Phase 2,Not Applicable 59467-70-8 4192
8
Propiverine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60569-19-9 4942
9
Fesoterodine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 286930-03-8, 286930-02-7 6918558
10
Tamsulosin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 106133-20-4 129211
11
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 738-70-5 5578
12
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 723-46-6 5329
13
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
14
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 6006 143
15
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
16
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
17
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
18
Ibuprofen Approved Phase 4 15687-27-1 3672
19
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Not Applicable 85721-33-1 2764
20
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3,Phase 2 67-20-9 5353830
21
Citalopram Approved Phase 4 59729-33-8 2771
22
Azithromycin Approved Phase 4 83905-01-5 55185 447043
23
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
24
Darifenacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 133099-04-4 444031
25
Silodosin Approved Phase 4 160970-54-7
26
Fosfomycin Approved Phase 4,Not Applicable 23155-02-4 446987
27
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613
28
Cefixime Approved, Investigational Phase 4,Phase 3 79350-37-1 5362065 54362
29
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
30
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
31 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
32
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
33
Alfuzosin Approved, Investigational Phase 4,Phase 3 81403-80-7 2092
34
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
35
Belladonna Approved, Experimental Phase 4
36
Acetaminophen Approved Phase 4 103-90-2 1983
37
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2 76-42-6 5284603
38
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
39
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
40
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
41
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
42
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 137-58-6 3676
43
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 100986-85-4 149096
44
Ofloxacin Approved Phase 4,Phase 3,Phase 1 82419-36-1 4583
45
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 93-14-1 3516
46
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2,Phase 3 56-12-2 119
47
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3 60142-96-3 3446
48
Methylene blue Approved, Investigational Phase 4 61-73-4
49
Methenamine Approved, Vet_approved Phase 4 100-97-0 4101
50
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456

Interventional clinical trials:

(show top 50) (show all 1764)
# Name Status NCT ID Phase Drugs
1 Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract Unknown status NCT02366676 Phase 4 IALURIL
2 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4 Deflux;Vantris
3 Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes Unknown status NCT02540707 Phase 4 solifenacin;mirabegron
4 MIrabegron With oveRACtive bLadder Symptoms in mEn Unknown status NCT02361502 Phase 4 mirabegron;placebo
5 Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity Unknown status NCT02009540 Phase 4 Botulinum toxin injected to bladder body;Botulinum toxin injected into trigone
6 Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients Unknown status NCT01876186 Phase 4 Solifenacin for 12 weeks;Solifenacin for 24 weeks
7 Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder Unknown status NCT01423838 Phase 4 Solifenacin;Oxybutynin
8 Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome Unknown status NCT00313924 Phase 4 DETRUSITOL
9 Surgical Treatment To Greater Anterior Vaginal Prolapse Unknown status NCT00676325 Phase 4
10 Comparative Study of Mesh Versus No Mesh in Prolapse Surgery Unknown status NCT00153257 Phase 4
11 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
12 The Assessment of POCD After TURBT Under Spinal Anesthesia Unknown status NCT03029676 Phase 4 benzodiazepines;opioid
13 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
14 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
15 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
16 Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome Unknown status NCT01157507 Phase 4 Intravesical injection of Botulinum A Toxin;Placebo
17 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
18 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis Completed NCT00919802 Phase 4 Oxytocin
19 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis Completed NCT02297100 Phase 4 Onabotulinumtoxin A
20 Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain Completed NCT02000401 Phase 4 Ketorolac Tromethamine
21 Ibuprofen Versus Mecillinam for Uncomplicated Cystitis Completed NCT01849926 Phase 4 Ibuprofen;Mecillinam
22 A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department Completed NCT01749605 Phase 4 Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days;ciprofloxacin 250 mg BID x 3 days
23 Botox as a Treatment for Interstitial Cystitis in Women Completed NCT00194610 Phase 4 Botox
24 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 Completed NCT01661621 Phase 4 Detrusitol 4 mg QD;Doxazosin 4 mg QD
25 Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
26 Investigation of the Effect of the Female Urinary Microbiome on Incontinence Completed NCT02835846 Phase 4 Estrogen Cream
27 Reproducibility Study of OABSS and Its Response to Treatment Completed NCT02667470 Phase 4 Solifenacin
28 Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. Completed NCT02468375 Phase 4 mirabegron 50mg
29 Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. Completed NCT02294396 Phase 4 Mirabegron tablet;Solifenacin tablet;Propiverine tablet;Imidafenacin tablet;Tolterodine capsule
30 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) Completed NCT02216214 Phase 4 Mirabegron;Placebo
31 A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) Completed NCT02138747 Phase 4 Mirabegron;Tolterodine ER
32 The Effect of Anticholinergics on Cognitive Function in the Elderly Completed NCT01922115 Phase 4 Trospium Chloride;Placebo
33 Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome Completed NCT01824420 Phase 4 Detrusitol 4mg QD and Oxybutynin ER 5mg QD;Detrusitol 4mg QD
34 A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients Completed NCT01745094 Phase 4 mirabegron;solifenacin
35 Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder Completed NCT01578304 Phase 4 Imidafenacin;Fesoterodine
36 The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB) Completed NCT01533597 Phase 4 Solifenacin;Solifenacin plus Tamsulosin
37 A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment Completed NCT01318837 Phase 4 solifenacin
38 Therapy of the Overactive Bladder Syndrome Completed NCT01314781 Phase 4 solifenacin
39 A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine Completed NCT01302067 Phase 4 Fesoterodine 8mg;Fesoterodine 4mg;Placebo
40 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. Completed NCT01302054 Phase 4 Fesoterodine 8 mg;Placebo
41 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial Completed NCT01178827 Phase 4 trospium chloride;oxybutynin IR;oxybutynin IR placebo
42 Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. Completed NCT01093534 Phase 4 Placebo;solifenacin
43 Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily Completed NCT01089751 Phase 4 trospium chloride;placebo
44 Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder Completed NCT01054222 Phase 4 Fesoterodine;Fesoterodine
45 Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency Completed NCT00979472 Phase 4 Solifenacin
46 Trospium Chloride XR in Obese Female Patients With Overactive Bladder Completed NCT00932022 Phase 4 Trospium Chloride, Extended Release (XR)
47 Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder Symptoms Completed NCT00928395 Phase 4
48 A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder Completed NCT00928070 Phase 4 Fesoterodine;Placebo
49 A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency Completed NCT00911937 Phase 4 Fesoterodine;Placebo
50 Validation of a Real-time Urodynamic Measure of Urinary Urgency Completed NCT00909428 Phase 4 Solifenacin Succinate

Search NIH Clinical Center for Bladder Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Disease:
Neo-Urinary Conduit�, smooth muscle cell 3D culture for bladder diseases
Embryonic/Adult Cultured Cells Related to Bladder Disease:
Neo-Urinary Conduit� PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder diseases

Sources

Genetic Tests for Bladder Disease

About this section
Sources

Anatomical Context for Bladder Disease

About this section

MalaCards organs/tissues related to Bladder Disease:

41
Testes, Kidney, Heart, Prostate, Smooth Muscle, Lung, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Disease:

19
The Bladder
Sources

Publications for Bladder Disease

About this section

Articles related to Bladder Disease:

(show top 50) (show all 167)
# Title Authors Year
1
Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease. ( 30105760 )
2018
2
Study on the Relation between Colorectal Cancer and Gall Bladder Disease. ( 28511430 )
2017
3
From gene discovery to new biological mechanisms: heparanases and congenital urinary bladder disease. ( 26315301 )
2015
4
Re: The Pharmacological rationale for combining muscarinic receptor antagonists and I^-adrenoceptor agonists in the treatment of airway and bladder disease. ( 25523672 )
2015
5
Prognostic Relevance of Human Telomerase Reverse Transcriptase (hTERT) Expression in Patients with Gall Bladder Disease and Carcinoma. ( 25854384 )
2015
6
Diagnosis of urinary bladder diseases in dogs by using two-dimensional and three-dimensional ultrasonography. ( 27047159 )
2015
7
The pharmacological rationale for combining muscarinic receptor antagonists and I^-adrenoceptor agonists in the treatment of airway and bladder disease. ( 24682092 )
2014
8
Financial cost to institutions on patients waiting for gall bladder disease surgery. ( 25603667 )
2014
9
Gastric pouch after simple or radical cystectomy for benign and malignant bladder disease. ( 25738108 )
2014
10
Genetics of human congenital urinary bladder disease. ( 23584850 )
2013
11
Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. ( 23013190 )
2012
12
Remodeling of the muscle layer (detrusor muscle) of hyperactive bladder disease in patients with benign prostatic hyperplasia. ( 23113284 )
2012
13
Muscarinic acetylcholine receptor M3 mutation causes urinary bladder disease and a prune-belly-like syndrome. ( 22077972 )
2011
14
The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. ( 22046200 )
2011
15
A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides. ( 21855919 )
2011
16
Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. ( 19634167 )
2010
17
Prevalence and characteristics associated with self-reported gall bladder disease in Mexican American elders: results from the Hispanic Established Populations for Epidemiologic Studies in the Elderly (H-EPESE). ( 19225267 )
2009
18
A four-year-old with Streptococcus pneumoniae--associated hemolytic uremic syndrome and gall bladder disease necessitating cholecystectomy. ( 19286616 )
2009
19
Overactive bladder disease: the urge for better therapies. ( 18500915 )
2008
20
Higher risk of gall bladder disease in oestrogen users. ( 28055473 )
2005
21
A study of the bacteriological pattern in gall bladder disease. 1986. ( 15485196 )
2004
22
Extracorporeal electromagnetic stimulation for urinary incontinence and bladder disease. ( 15088922 )
2003
23
In vivo optical coherence tomography feasibility for bladder disease. ( 11832776 )
2002
24
Bladder disease: A report based on the smooth muscle function in health and disease satellite meeting to the International Congress of Physiology. ( 12734603 )
2001
25
Electromagnetic pelvic floor stimulation for urinary incontinence and bladder disease. ( 11795645 )
2001
26
Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. ( 11167643 )
2001
27
Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. ( 11564042 )
2001
28
EAU - 15th Congress. Urinary incontinence and bladder disease. ( 16080050 )
2000
29
Review article: epidemiology of gall-bladder disease--role of intestinal transit. ( 10902996 )
2000
30
Nitric oxide synthase expression in neurogenic bladder disease: a pilot study. ( 10218094 )
1999
31
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen. ( 9471136 )
1998
32
Gall bladder disease and ABO blood group. ( 10456157 )
1997
33
Long-term follow-up after clam ileocystoplasty. Complications and results including some quality-of-life parameters for 32 patients treated for neuropathic and nonneuropathic bladder disease. ( 8178380 )
1994
34
Alterations to the electrophysiology of isolated human detrusor smooth muscle cells in bladder disease. ( 8309000 )
1994
35
Risk factors for symptomatic gall bladder disease. ( 7959216 )
1994
36
Cigarette smoking and parity as risk factors for the development of symptomatic gall bladder disease in women: results of the Royal College of General Practitioners' oral contraception study. ( 8307429 )
1994
37
Risk factors for the development of gall bladder disease. ( 18668936 )
1994
38
Is gallbladder ejection fraction a reliable predictor of acalculous gall bladder disease? ( 8321495 )
1993
39
Superficial bladder disease: case studies and therapeutic advances. ( 1466118 )
1992
40
Is gall bladder ejection fraction a reliable predictor of acalculous gall bladder disease? ( 1465273 )
1992
41
Gall bladder disease as seen in a Harare referral hospital centre. ( 2225019 )
1990
42
Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. ( 2925272 )
1989
43
Gall bladder disease: an analytical report of 250 cases. ( 2634700 )
1989
44
Gall bladder disease in Zimbabwe. ( 3194957 )
1988
45
Parathyroid hormone like bioactivity measured by cytochemical bioassay in a patient with malignant bladder disease. ( 3248932 )
1988
46
Looking for gall bladder disease in the patient's iris. ( 3147081 )
1988
47
Painful bladder disease: clinical and pathoanatomical differences in 115 patients. ( 3625848 )
1987
48
Urinary excretion of a metabolite of histamine (1,4-methyl-imidazole-acetic-acid) in painful bladder disease. ( 3567484 )
1987
49
Prospective study of intravesical dimethyl sulphoxide in the treatment of chronic inflammatory bladder disease. ( 3828709 )
1987
50
Urine eosinophil cationic protein in painful bladder disease. ( 3304514 )
1987
Sources

Variations for Bladder Disease

About this section
Sources

Expression for Bladder Disease

About this section
Search GEO for disease gene expression data for Bladder Disease.
Sources

Pathways for Bladder Disease

About this section

Pathways related to Bladder Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Gastric cancer 37
Show member pathways
 12.22 CDH1 GSTM1 GSTT1 TERT TP53
2
Pathways in cancer 37
12.15 CDH1 FGFR3 GSTM1 GSTT1 TERT TP53
3
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 11.83 FGFR3 HBEGF TERT TP53
4
Platinum drug resistance 37
11.3 GSTM1 GSTT1 TP53
5
Bladder cancer 37 1
10.88 CDH1 FGFR3 HBEGF TP53 UPK3A
Sources

GO Terms for Bladder Disease

About this section

Cellular components related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.17 CHRM3 FGFR3 HBEGF SLC3A1 SLC7A9 TRPV1

Biological processes related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 L-alpha-amino acid transmembrane transport GO:1902475 9.16 SLC3A1 SLC7A9
2 replicative senescence GO:0090399 8.96 TERT TP53
3 L-cystine transport GO:0015811 8.62 SLC3A1 SLC7A9

Molecular functions related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 L-cystine transmembrane transporter activity GO:0015184 8.62 SLC3A1 SLC7A9
Sources

Sources for Bladder Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....